Document Detail

Radiotherapy for stage T3b transitional cell carcinoma of the bladder.
MedLine Citation:
PMID:  8734736     Owner:  NLM     Status:  MEDLINE    
The role of radiotherapy for the treatment of clinical stage T3b transitional cell carcinoma of the bladder is controversial. The options range from definitive radiotherapy alone, to preoperative radiotherapy and cystectomy, to chemotherapy and radiation for bladder preservation. Our data show that long-term local control after definitive radiotherapy is only 27% and that death attributable to local-regional failure in this setting is 43%. Thus, definitive radiotherapy is only used in patients who are considered poor candidates for surgical and chemotherapy procedures. Preoperative radiotherapy (PREOP) has been studied in a number of randomized series, all of which failed to establish an improvement in patient outcome over those treated with radical cystectomy alone (CYST). However, these studies are subject to criticism, mostly because of poor patient accrual and low numbers of patients available for the analyses. A retrospective review of patients treated at MD Anderson Cancer Center indicates that local control is superior with PREOP as compared with CYST. An analysis of the impact of local control on distant metastasis rates in patients treated with CYST showed that local control was an independent correlate of distant metastasis and survival. Thus, preoperative radiotherapy may be beneficial to patients with late-stage muscle-invasive bladder cancer by securing local control and reducing distant metastasis rates as a result. The success of bladder preservation for stage T3b patients rests with the ability to select patients with radiosensitive tumors. To this end, the immunohistochemical staining status of tumor p53 and pRB was investigated in patients treated with PREOP. Abnormal pRB expression was very strongly related to radiation response, whereas altered p53 expression was associated with high distant metastasis-free and overall survival rates. These two molecular markers were complementary and show promise in facilitating the selection of late-stage patients for bladder preservation.
A Pollack; G Z Zagars
Related Documents :
8558186 - Neoadjuvant combined modality program with selective organ preservation for invasive bl...
12057106 - Locally advanced and metastatic bladder cancer.
18722046 - Bladder preservation in selected patients with muscle-invasive bladder cancer by comple...
9008026 - Carcinoma of the bladder in patients under 25 years of age.
1720656 - Vab-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic semino...
20414926 - Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small ce...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in urologic oncology     Volume:  14     ISSN:  1081-0943     ISO Abbreviation:  Semin. Urol. Oncol.     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-10-17     Completed Date:  1996-10-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9514993     Medline TA:  Semin Urol Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  86-95     Citation Subset:  IM    
Department of Radiotherapy, University of Texas MD Anderson Medical Center, Houston 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carcinoma, Transitional Cell / mortality,  pathology,  radiotherapy*
Neoplasm Staging
Radiotherapy, Adjuvant
Survival Rate
Urinary Bladder / pathology
Urinary Bladder Neoplasms / mortality,  pathology,  radiotherapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of chemotherapy in the management of the patient with T3b bladder cancer.
Next Document:  What to do if the lymph nodes are positive.